Melbourne to host world's largest life sciences supercomputer in $100 million investment.

A research director at Los Alamos National Laboratories said the addition of a peta-scale supercomputer is as big a leap forward as when scientists got their hands on their first computer ever.

Engineers and technicians at IBM are assembling the final pieces of what they hope will soon become the world's most powerful supercomputer - doubling the speed of the today's fastest machine.

Protein science meets computer gaming as researchers Foldit.

Research grid could lead to improved drug research and safer clinical trials for cancer and other diseases.

It's not the $1000 genome just yet, but Applied Biosystems says it's getting there.

Canadian bioinformaticians develop new tools to create 3D structure of RNA.

Melbourne company Invision IT says its Evado software overcomes EDC shortcomings.

The evolutionary history of SARS suggests that bats, and not civet cats, were the original source of the virus.

Analysis of protein interactions show pathogens preferentially interact with hubs and bottlenecks.

Australia's great e-health vision continues to stall with new research showing that greater use of ICT in the health sector could generate savings worth more than $1.5 billion per annum.

The National Blood Authority has refreshed its IT infrastructure to cope with the increasing complexity of supply.

The research community is becoming more sophisticated in the way they approach intellectual property and industry partnerships. Ruth Beran looks at how technology transfer has changed, where it is going and the challenges it faces.

Biotechnology has provided a solution to the problem of how to get science to the market without compromising research, writes editor-in-chief Iain Scott.

Kiran Mazumdar-Shaw told AusBiotech 2005 about opportunities for Australian biotech to work with India.

US venture capitalist Osagie Imasogie told AusBiotech 2005 that biotech companies need to get aggressive when it comes to finding opportunities.

Pfizer's Peter Corr told the AusBiotech 2005 conference that big pharma and biotech are part of a delicate ecosystem -- and both have key roles to play.

The latest medical technology is all very well - if you can afford it. Susan Williamson looks at how one Australian group is coming up with practical healthcare solutions for the developing world.

Should Australia lift its ban on therapeutic cloning? Few topics in Australian science have generated such strong opinions. Ruth Beran reports.

The Australian Stock Exchange has created a market that attracts not only local biotechnology companies, but also gives opportunities to foreign companies that would be unable to attract capital in their own markets. Helen Schuller reports.

How did a chemistry PhD become one of the 50 most powerful women in business by hooking up the world's largest computer company with the life sciences? Kate McDonald spoke to IBM's Carol Kovac, who admits to being rather excited about the world of biology.

Cochlear boss Chris Roberts has spent 30 years at Australia's leading device companies -- but that doesn't mean he has stopped learning, as Helen Schuller discovers.

Kevin Davies spoke with Jonathan Rothberg, the founder of 454 Life Sciences, on the eve of the publication of his company's landmark paper in Nature.

Australian Biotechnology News editor-in-chief Iain Scott spoke with renowned industry analyst Cynthia Robbins-Roth about what it will take to keep biotech alive.

Ruth Beran discovers how one of Australia's great bioentrepreneurs has moved from inspiring shareholders to inspiring a nation.

The thing about bioinformatics, according to Prof Terry Speed, is that it tends to attract people from a variety of disciplines, such as physicists with programming skills not interested in a career in defence, or mathematicians with a practical bent.

When Eric Jakobsson took a new job with the National Institutes of Health, part of the agreement was that he would split his weeks between Bethesda, Maryland, and his job at the University of Illinois, jetting back and forth between the two.

History students and trivia buffs in the distant future time will be grateful for one of history's little coincidences -- the Human Genome Project will be completed this year, 2003, a neat half-century after the elucidation of the structure of DNA.

Nobel Laureate Prof Peter Doherty is lending his name to a new prize to be awarded at Australia's first Commercialisation Forum and Fair of Ideas, which started in Sydney today and runs to March 28.

Phil Batterham is a skilled and meticulous organiser, with an understanding of the value of theatre. When the University of Melbourne geneticist flew to Beijing in 1998 for the 18th International Congress of Genetics, he had already spent two years organising Australia's bid to bring the world's biggest genetics festival to Melbourne in 2003.

Microarray technology is now a major tool available to the geneticist. The technology allows researchers to look at the expression of a vast array of genes simultaneously, and myriad applications have been found in the last few years. But deciding on the best microarray system for the needs of the research is a difficult task, with several choices available.

When you think of the Human Genome Project, images of banks of sequencing machines pumping out millions of base pairs of information comes to mind. According to Dr John Barlow, Melbourne divisional manager of the Australian Genome Research Facility, state-of-the-art sequencing is still largely electrophoresis-based. However, sequencers have come a long way since the days of pouring your own sequencing gel and using radioactive dideoxynucleotides.

The task of creating specialised software tools to decipher the complexities of genes and proteins until recently has been a do-it-yourself project for the bio-research community.

Capillary electrophoresis (CE) is a technique that allows researchers to separate analytes based on their differential mobilities in aqueous media when an electric field is applied.

Sample capacity is at the heart of the decision on what capillary electrophoresis system best fits a lab's needs.